Rhythm Pharmaceuticals Convenes Inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence (IMPROVE) 2022
October 12, 2022 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Approximately 100 European health care professionals invited to discuss recent scientific developments in rare pathway-related obesities -- -- Rhythm presents analysis of Phase 2 Basket Study...
Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development
October 06, 2022 16:02 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
October 06, 2022 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)
September 23, 2022 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Book developed in collaboration with the Bardet-Biedl Syndrome Foundation -- -- BBS Global Day on Sept. 24 coordinated by BBS International -- BOSTON, Sept. 23, 2022 (GLOBE NEWSWIRE) --...
Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering
September 19, 2022 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and...
Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022
September 19, 2022 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- CARE-BBS multi-country survey of 242 caregivers of individuals with Bardet-Biedl syndrome (BBS) provides extensive details on impact of hyperphagia and obesity -- -- New analyses of Phase 3 data...
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering
September 14, 2022 22:20 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and...
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering
September 14, 2022 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
September 07, 2022 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
September 06, 2022 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
-- Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) -- -- EC authorization for BBS makes Rhythm eligible to receive second $37.5M tranche under Revenue Interest...